Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Rivastigmine in Toxic Anticholinergic Delirium
NCT07545382Phase 4Completed
- Sponsor
- Alexandria University
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in delirium, sponsored by Alexandria University. Started Dec 2025; status: completed.
02
Drugs
rivastigmine
03
Conditions
delirium
Beyond the preview
Go deeper on NCT07545382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545382.